Factor Xa inhibitor antidote: Difference between revisions

Jump to navigation Jump to search
No edit summary
WikiBot (talk | contribs)
No edit summary
 
(3 intermediate revisions by 2 users not shown)
Line 2: Line 2:


{{CMG}}
{{CMG}}
{{EH}}
'''''Synonyms and keywords:''''' Factor Xa inhibitor antidote, factor Xa inhibitor reversal agent, FXa inhibitor antidote, Factor 10a inhibitor antidote
'''''Synonyms and keywords:''''' Factor Xa inhibitor antidote, factor Xa inhibitor reversal agent, FXa inhibitor antidote, Factor 10a inhibitor antidote
 
==Overview==
Direct Factor Xa inhibitors include [[Rivaroxaban]], [[Betrixaban]], [[Apixaban]] and [[Edoxaban]].  These agents bind directly to a serine residue of [[Factor Xa]] and inhibit the ability of [[Factor Xa]] to bind to the active site. They work by steric hinderance. They bind reversibly. Thus there is an equilibrium where these inhibitor molecules are binding and falling off of the [[Factor Xa]] molecule.  Indirect inhibitors like [[fondaparinux]] and [[enoxaperin]] require [[antithrombin 3]] ([[AT3]]) in addition.
Direct Factor Xa inhibitors include [[Rivaroxaban]], [[Betrixaban]], [[Apixaban]] and [[Edoxaban]].  These agents bind directly to a serine residue of [[Factor Xa]] and inhibit the ability of [[Factor Xa]] to bind to the active site. They work by steric hinderance. They bind reversibly. Thus there is an equilibrium where these inhibitor molecules are binding and falling off of the [[Factor Xa]] molecule.  Indirect inhibitors like [[fondaparinux]] and [[enoxaperin]] require [[antithrombin 3]] ([[AT3]]) in addition.


==Mechanism of Action==
==Mechanism of Action==
  Normal  0          false  false  false    EN-US  X-NONE  X-NONE                                      MicrosoftInternetExplorer4                                                                                                                                                                                                                                                                                                                            This is a decoy mechanism whereby the antidote binds to the Factor Xa inhibitor and soaks it up so it doesn’t bind and inhibit the Factor Xa. The binding to the Factor Xa inhibitor is reversible. The avidity of the binding is about the same as the avidity with which the Factor Xa inhibitor binds to the Factor Xa molecule. The antidote soaks up or binds all of the Factor Xa inhibitor by binding to it. As a Factor Xa inhibitor falls off of the Factor Xa molecule, it gets soaked up or bound to the antidote. The antidote does not appear to be procoagulant or anticoagulant.
This is a "decoy" mechanism whereby the antidote binds to the Factor Xa inhibitor and soaks it up so it doesn’t bind and inhibit the Factor Xa. The binding to the Factor Xa inhibitor is reversible. The avidity of the binding is about the same as the avidity with which the Factor Xa inhibitor binds to the Factor Xa molecule. The antidote soaks up or binds all of the Factor Xa inhibitor by binding to it. As a Factor Xa inhibitor falls off of the Factor Xa molecule, it gets soaked up or bound to the antidote. The antidote does not appear to be procoagulant or anticoagulant.


==References==
==References==

Latest revision as of 20:49, 16 November 2011

WikiDoc Resources for Factor Xa inhibitor antidote

Articles

Most recent articles on Factor Xa inhibitor antidote

Most cited articles on Factor Xa inhibitor antidote

Review articles on Factor Xa inhibitor antidote

Articles on Factor Xa inhibitor antidote in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Factor Xa inhibitor antidote

Images of Factor Xa inhibitor antidote

Photos of Factor Xa inhibitor antidote

Podcasts & MP3s on Factor Xa inhibitor antidote

Videos on Factor Xa inhibitor antidote

Evidence Based Medicine

Cochrane Collaboration on Factor Xa inhibitor antidote

Bandolier on Factor Xa inhibitor antidote

TRIP on Factor Xa inhibitor antidote

Clinical Trials

Ongoing Trials on Factor Xa inhibitor antidote at Clinical Trials.gov

Trial results on Factor Xa inhibitor antidote

Clinical Trials on Factor Xa inhibitor antidote at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Factor Xa inhibitor antidote

NICE Guidance on Factor Xa inhibitor antidote

NHS PRODIGY Guidance

FDA on Factor Xa inhibitor antidote

CDC on Factor Xa inhibitor antidote

Books

Books on Factor Xa inhibitor antidote

News

Factor Xa inhibitor antidote in the news

Be alerted to news on Factor Xa inhibitor antidote

News trends on Factor Xa inhibitor antidote

Commentary

Blogs on Factor Xa inhibitor antidote

Definitions

Definitions of Factor Xa inhibitor antidote

Patient Resources / Community

Patient resources on Factor Xa inhibitor antidote

Discussion groups on Factor Xa inhibitor antidote

Patient Handouts on Factor Xa inhibitor antidote

Directions to Hospitals Treating Factor Xa inhibitor antidote

Risk calculators and risk factors for Factor Xa inhibitor antidote

Healthcare Provider Resources

Symptoms of Factor Xa inhibitor antidote

Causes & Risk Factors for Factor Xa inhibitor antidote

Diagnostic studies for Factor Xa inhibitor antidote

Treatment of Factor Xa inhibitor antidote

Continuing Medical Education (CME)

CME Programs on Factor Xa inhibitor antidote

International

Factor Xa inhibitor antidote en Espanol

Factor Xa inhibitor antidote en Francais

Business

Factor Xa inhibitor antidote in the Marketplace

Patents on Factor Xa inhibitor antidote

Experimental / Informatics

List of terms related to Factor Xa inhibitor antidote

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Synonyms and keywords: Factor Xa inhibitor antidote, factor Xa inhibitor reversal agent, FXa inhibitor antidote, Factor 10a inhibitor antidote

Overview

Direct Factor Xa inhibitors include Rivaroxaban, Betrixaban, Apixaban and Edoxaban. These agents bind directly to a serine residue of Factor Xa and inhibit the ability of Factor Xa to bind to the active site. They work by steric hinderance. They bind reversibly. Thus there is an equilibrium where these inhibitor molecules are binding and falling off of the Factor Xa molecule. Indirect inhibitors like fondaparinux and enoxaperin require antithrombin 3 (AT3) in addition.

Mechanism of Action

This is a "decoy" mechanism whereby the antidote binds to the Factor Xa inhibitor and soaks it up so it doesn’t bind and inhibit the Factor Xa. The binding to the Factor Xa inhibitor is reversible. The avidity of the binding is about the same as the avidity with which the Factor Xa inhibitor binds to the Factor Xa molecule. The antidote soaks up or binds all of the Factor Xa inhibitor by binding to it. As a Factor Xa inhibitor falls off of the Factor Xa molecule, it gets soaked up or bound to the antidote. The antidote does not appear to be procoagulant or anticoagulant.

References

Template:WH Template:WS